Tocilizumab (MRA-SC) ( DrugBank: Tocilizumab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 40 | 高安動脈炎 | 1 |
40. 高安動脈炎
臨床試験数 : 24 / 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-142616 | 02/10/2014 | 23/07/2014 | Phase III Study of MRA-SC in Patients with Takayasu Arteritis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis | Takayasu Arteritis | Intervention name : tocilizumab (MRA-SC) INN of the intervention : tocilizumab Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo/W, SC | Chugai Pharmaceutical Co., Ltd. | NULL | complete | 12 | BOTH | 34 | Phase 3 | Japan |